Skip to main content

HealthTimes

Health News HIV/AIDS

Global Leaders Come Together at IAS 2025 in Kigali

Michael Gwarisa

By Health Times Reporter in Kigali, Rwanda The 13th International AIDS Society (IAS) 2025 conference opened today in Kigali with a powerful call to action: ‘Communities must lead the fight to end HIV’. Over 5,000 scientists, activists, and policymakers gathered to celebrate scientific progress while demanding urgent investment in grassroots solutions. Rosemary Mburu, a seasoned HIV

Read More
Health News HIV/AIDS

Zimbabwe’s HIV Self-Testing Initiative Makes Up 15% of New Diagnoses

Michael Gwarisa

By Shamiso Yikoniko in Kigali, Rwanda Zimbabwe’s proactive efforts to expand HIV self-testing (HIVST) have led to 15 percent of all new HIV diagnoses in the country this year (2024), according to recent government data shared at the 13th International AIDS Society (IAS) Conference in Kigali, Rwanda. The findings highlight the strategy’s success in reaching

Read More
Health News HIV/AIDS

Zimbabwe Ranks Second Globally for HIV-Related Stigma, UNAIDS Report Finds

Michael Gwarisa

By Kuda Pembere Zimbabwe has the second highest proportion of people who experienced HIV-related stigma while seeking HIV or other health services in the past year, according to the latest UNAIDS report. Drawing from the People Living with HIV Stigma Index 2.0 (2020–2024), the UNAIDS Global AIDS Update 2025 shows that Iran tops the list

Read More
Health News HIV/AIDS

NAC Fears HIV Setbacks Despite Global Praise

Michael Gwarisa

By Michael Gwarisa  Zimbabwe has earned international praise for its HIV response, with the latest UNAIDS Global AIDS Update 2025 placing the country among a select group on track to meet the ambitious 2030 target of ending AIDS as a public health threat. However, health authorities at home have issued a stark warning: the next

Read More
Global Health Health News HIV/AIDS

Gilead’s Secrecy Over HIV Prevention Shot Sparks Global Outrage

Michael Gwarisa

By Staff Reporter  Gilead Sciences has come under fire after announcing a secretive deal to supply its long-acting injectable HIV prevention drug, lenacapavir (LEN-LA), to the Global Fund to Fight AIDS, Tuberculosis and Malaria. The agreement—shrouded in indefinite price secrecy—has been widely condemned by civil society organisations, health advocates, and global health experts who warn

Read More
Health News HIV/AIDS

National AIDS Council Holds 2023 AGM, Sets Sights on 2030 HIV Targets

Michael Gwarisa

By Michael Gwarisa The National AIDS Council (NAC) on Thursday held its long-awaited Annual General Meeting (AGM) for 2023, following a year-long hiatus after the dissolution of the previous board. The AGM, which had been delayed throughout 2024, marked a significant turning point in NAC’s operations as the newly appointed board seeks to restore momentum

Read More
Features Health News HIV/AIDS Tech-Health News

Tablets and Tenacity: How Young HIV Peer Supporters Are Transforming Treatment Adherence in Rural Zimbabwe

Michael Gwarisa

By Michael Gwarisa in Gutu Every morning, 20-year-old Christin Madombi wakes up with a mission. From her modest home in Gutu’s Mutero area, she powers up her tablet and scans through a list of peers—young people just like her, living with HIV. She has 24 peers assigned to her under the Community Adolescent Treatment Supporter

Read More
Features Health News HIV/AIDS

Suspended HIV Services Resume in Masvingo as CAB-LA, Vaginal Ring Return for Key Populations

Michael Gwarisa

By Michael Gwarisa, recently in Masvingo For the past 12 months, Wellington*, a 41-year-old Masvingo man who has sex with men (MSM) and a male sex worker, has relied on oral Pre-Exposure Prophylaxis (PrEP) to reduce his risk of HIV infection. He has also used condoms and occasionally Post-Exposure Prophylaxis (PEP). At the start of

Read More
Global Health Health News HIV/AIDS

FDA approves twice-a-year injection for HIV prevention

Michael Gwarisa

CNN — A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug Administration to be used to prevent HIV. Gilead Sciences, maker of the drug, announced that a twice-a-year injection of lenacapavir has been approved in the United States for HIV prevention under the brand name Yeztugo.

Read More
Features Health News HIV/AIDS

How Masvingo’s Health Facilities Are Giving Sex Workers a Lifeline Amid Donor Cuts

Michael Gwarisa

By Michael Gwarisa in Masvingo She is nine months pregnant and could give birth any day now, yet Melody Mhlanga* still sells sex to survive. The 25-year-old from Gutu, Masvingo Province, found herself thrust into the world of sex work three months ago after her marriage collapsed. With no income, no support, and a baby

Read More